[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.5483/BMBRep.2013.46.5.077

SERCA2a: a prime target for modulation of cardiac contractility during heart failure

Park, Woo Jin (Global Research Laboratory and College of Life Sciences, Gwangju Institute of Science and Technology)
Oh, Jae Gyun (Global Research Laboratory and College of Life Sciences, Gwangju Institute of Science and Technology)

Publication Information

BMB Reports / v.46, no.5, 2013 , pp. 237-243 More about this Journal

Abstract

Heart failure is one of the leading causes of sudden death in developed countries. While current therapies are mostly aimed at mitigating associated symptoms, novel therapies targeting the subcellular mechanisms underlying heart failure are emerging. Failing hearts are characterized by reduced contractile properties caused by impaired $Ca^{2+}$ cycling between the sarcoplasm and sarcoplasmic reticulum (SR). Sarcoplasmic/endoplasmic reticulum $Ca^{2+}$ ATPase 2a (SERCA2a) mediates $Ca^{2+}$ reuptake into the SR in cardiomyocytes. Of note, the expression level and/or activity of SERCA2a, translating to the quantity of SR $Ca^{2+}$ uptake, are significantly reduced in failing hearts. Normalization of the SERCA2a expression level by gene delivery has been shown to restore hampered cardiac functions and ameliorate associated symptoms in pre-clinical as well as clinical studies. SERCA2a activity can be regulated at multiple levels of a signaling cascade comprised of phospholamban, protein phosphatase 1, inhibitor-1, and $PKC{\alpha}$ . SERCA2 activity is also regulated by post-translational modifications including SUMOylation and acetylation. In this review, we will highlight the molecular mechanisms underlying the regulation of SERCA2a activity and the potential therapeutic modalities for the treatment of heart failure.

Keywords

Inhibitor-1; Phospholamban; $PKC{\alpha}$ ; Protein phosphatase 1; SERCA2a;

Citations & Related Records

Reference

1	Luo, W., Grupp, I. L., Harrer, J., Ponniah, S., Grupp, G., Duffy, J. J., Doetschman, T. and Kranias, E. G. (1994) Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ. Res. 75, 401-409. DOI ScienceOn
2	Luo, W., Wolska, B. M., Grupp, I. L., Harrer, J. M., Haghighi, K., Ferguson, D. G., Slack, J. P., Grupp, G., Doetschman, T., Solaro, R. J. and Kranias, E. G. (1996) Phospholamban gene dosage effects in the mammalian heart. Circ. Res. 78, 839-847. DOI ScienceOn
3	MacDougall, L. K., Jones, L. R. and Cohen, P. (1991) Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban. Eur. J. Biochem. 196, 725-734. DOI ScienceOn
4	Gwathmey, J. K., Copelas, L., MacKinnon, R., Schoen, F. J., Feldman, M. D., Grossman, W. and Morgan, J. P. (1987) Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ. Res. 61, 70-76. DOI ScienceOn
5	Haghighi, K., Kolokathis, F., Pater, L., Lynch, R. A., Asahi, M., Gramolini, A. O., Fan, G. C., Tsiapras, D., Hahn, H. S., Adamopoulos, S., Liggett, S. B., Dorn, G. W. 2nd, MacLennan, D. H., Kremastinos, D. T. and Kranias, E. G. (2003) Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111, 869-876. DOI ScienceOn
6	Hajjar, R. J., Schmidt, U., Kang, J. X., Matsui, T. and Rosenzweig, A. (1997) Adenoviral gene transfer of phospholamban in isolated rat cardiomyocytes. Rescue effects by concomitant gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. Circ. Res. 81, 145-153. DOI ScienceOn
7	Hajjar, R. J., Schmidt, U., Matsui, T., Guerrero, J. L., Lee, K. H., Gwathmey, J. K., Dec, G. W., Semigran, M. J. and Rosenzweig, A. (1998) Modulation of ventricular function through gene transfer in vivo. Proc. Natl. Acad. Sci.U.S.A. 95, 5251-5256. DOI
8	Hambleton, M., Hahn, H., Pleger, S. T., Kuhn, M. C., Klevitsky, R., Carr, A. N., Kimball, T. F., Hewett, T. E., Dorn, G. W. 2nd, Koch, W. J. and Molkentin, J. D. (2006) Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation 114, 574-582. DOI ScienceOn
9	Nicolaou, P., Rodriguez, P., Ren, X., Zhou, X., Qian, J., Sadayappan, S., Mitton, B., Pathak, A., Robbins, J., Hajjar, R. J., Jones, K. and Kranias, E. G. (2009) Inducible expression of active protein phosphatase-1 inhibitor-1 en hances basal cardiac function and protects against ischemia/ reperfusion injury. Circ. Res. 104, 1012-1020. DOI ScienceOn
10	Oh, J. G., Kim, J., Jang, S. P., Nguen, M., Yang, D. K., Jeong, D., Park, Z. Y., Park, S. G., Hajjar, R. J. and Park, W. J. (2013) Decoy peptides targeted to protein phosphatase 1 inhibit dephosphorylation of phospholamban in cardiomyocytes. J. Mol. Cell Cardiol. 56, 63-71. DOI ScienceOn
11	Pathak, A., del Monte, F., Zhao, W., Schultz, J. E., Lorenz, J. N., Bodi, I., Weiser, D., Hahn, H., Carr, A. N., Syed, F., Mavila, N., Jha, L., Qian, J., Marreez, Y., Chen, G., McGraw, D. W., Heist, E. K., Guerrero, J. L., DePaoli-Roach, A. A., Hajjar, R. J. and Kranias, E. G. (2005) Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ. Res. 96, 756-766. DOI ScienceOn
12	Periasamy, M., Reed, T. D., Liu, L. H., Ji, Y., Loukianov, E., Paul, R. J., Nieman, M. L., Riddle, T., Duffy, J. J., Doetschman, T., Lorenz, J. N. and Shull, G. E. (1999) Impaired cardiac performance in heterozygous mice with a null mutation in the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 (SERCA2) gene. J. Biol. Chem. 274, 2556-2562. DOI ScienceOn
13	Prunier, F., Kawase, Y., Gianni, D., Scapin, C., Danik, S. B., Ellinor, P. T., Hajjar, R. J. and Del Monte, F. (2008) Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump overexpression in a porcine model of ischemia reperfusion. Circulation 118, 614-624. DOI ScienceOn
14	Kadambi, V. J., Ponniah, S., Harrer, J. M., Hoit, B. D., Dorn, G. W. 2nd, Walsh, R. A. and Kranias, E. G. (1996) Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J. Clin. Invest. 97, 533-539. DOI
15	Yano, M., Yamamoto, T., Ikemoto, N. and Matsuzaki, M. (2005) Abnormal ryanodine receptor function in heart failure. Pharmacol. Ther. 107, 377-391. DOI ScienceOn
16	Rodriguez, P., Mitton, B., Nicolaou, P., Chen, G. and Kranias, E. G. (2007) Phosphorylation of human inhibitor- 1 at Ser67 and/or Thr75 attenuates stimulatory effects of protein kinase A signaling in cardiac myocytes. Am. J. Physiol. Heart. Circ. Physiol. 293, H762-769. DOI ScienceOn
17	Rodriguez, P., Mitton, B., Waggoner, J. R. and Kranias, E. G. (2006) Identification of a novel phosphorylation site in protein phosphatase inhibitor-1 as a negative regulator of cardiac function. J. Biol. Chem. 281, 38599-38608. DOI ScienceOn
18	Kawase, Y., Ly, H. Q., Prunier, F., Lebeche, D., Shi, Y., Jin, H., Hadri, L., Yoneyama, R., Hoshino, K., Takewa, Y., Sakata, S., Peluso, R., Zsebo, K., Gwathmey, J. K., Tardif, J. C., Tanguay, J. F. and Hajjar, R. J. (2008) Reversal of cardiac dysfunction after long- term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J. Am. Coll. Cardiol. 51, 1112-1119. DOI ScienceOn
19	Schultz Jel, J., Glascock, B. J., Witt, S. A., Nieman, M. L., Nattamai, K. J., Liu, L. H., Lorenz, J. N., Shull, G. E., Kimball, T. R. and Periasamy, M. (2004) Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity. Am. J. Physiol. Heart. Circ. Physiol. 286, H1146-1153. DOI
20	Steenaart, N. A., Ganim, J. R., Di Salvo, J. and Kranias, E. G. (1992) The phospholamban phosphatase associated with cardiac sarcoplasmic reticulum is a type 1 enzyme. Arch. Biochem. Biophys. 293, 17-24. DOI ScienceOn
21	Mathers, C. D., Boerma, T. and Ma Fat, D. (2009) Global and regional causes of death. Br. Med. Bull. 92, 7-32. DOI ScienceOn
22	Mathers, C. D. and Loncar, D. (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3, e442. DOI
23	Mercadier, J. J., Lompre, A. M., Duc, P., Boheler, K. R., Fraysse, J. B., Wisnewsky, C., Allen, P. D., Komajda, M. and Schwartz, K. (1990) Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure. J. Clin. Invest. 85, 305-309. DOI ScienceOn
24	Movsesian, M. A., Leveille, C., Krall, J., Colyer, J., Wang, J. H. and Campbell, K. P. (1990) Identification and characterization of proteins in sarcoplasmic reticulum from normal and failing human left ventricles. J. Mol. Cell Cardiol. 22, 1477-1485. DOI ScienceOn
25	Lehnart, S. E., Maier, L. S. and Hasenfuss, G. (2009) Abnormalities of calcium metabolism and myocardial contractility depression in the failing heart. Heart. Fail. Rev. 14, 213-224. DOI
26	Kho, C., Lee, A., Jeong, D., Oh, J. G., Chaanine, A. H., Kizana, E., Park, W. J. and Hajjar, R. J. (2011) SUMO1- dependent modulation of SERCA2a in heart failure. Nature 477, 601-605. DOI ScienceOn
27	Ladage, D., Tilemann, L., Ishikawa, K., Correll, R. N., Kawase, Y., Houser, S. R., Molkentin, J. D. and Hajjar, R. J. (2011) Inhibition of PKCalpha/beta with ruboxistaurin antagonizes heart failure in pigs after myocardial infarction injury. Circ. Res. 109, 1396-1400. DOI ScienceOn
28	Lehnart, S. E. (2007) Novel targets for treating heart and muscle disease: stabilizing ryanodine receptors and preventing intracellular calcium leak. Curr. Opin. Pharmacol. 7, 225-232. DOI ScienceOn
29	Limas, C. J., Olivari, M. T., Goldenberg, I. F., Levine, T. B., Benditt, D. G. and Simon, A. (1987) Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy. Cardiovasc Res. 21, 601-605. DOI ScienceOn
30	Liu, Q., Chen, X., Macdonnell, S. M., Kranias, E. G., Lorenz, J. N., Leitges, M., Houser, S. R. and Molkentin, J. D. (2009) Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Circ. Res. 105, 194-200. DOI ScienceOn
31	Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T. and Murray, C. J. (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367, 1747-1757. DOI ScienceOn
32	El-Armouche, A., Rau, T., Zolk, O., Ditz, D., Pamminger, T., Zimmermann, W. H., Jäckel, E., Harding, S. E., Boknik, P., Neumann, J. and Eschenhagen, T. (2003) Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. FASEB J. 17, 437-439.
33	Neumann, J., Eschenhagen, T., Jones, L. R., Linck, B., Schmitz, W., Scholz, H. and Zimmermann, N. (1997) Increased expression of cardiac phosphatases in patients with end-stage heart failure. J. Mol. Cell Cardiol. 29, 265-272. DOI ScienceOn
34	Neumann, J. Gupta, R. C., Schmitz, W., Scholz, H., Nairn, A. C. and Watanabe, A. M. (1991) Evidence for isoproterenol-induced phosphorylation of phosphatase inhibitor-1 in the intact heart. Circ. Res. 69, 1450-1457. DOI ScienceOn
35	Carr, A. N., Schmidt, A. G., Suzuki, Y., del Monte, F., Sato, Y., Lanner, C., Breeden, K., Jing, S. L., Allen, P. B., Greengard, P., Yatani, A., Hoit, B. D., Grupp, I. L., Hajjar, R. J., DePaoli-Roach, A. A. and Kranias, E. G. (2002) Type 1 phosphatase, a negative regulator of cardiac function. Mol. Cell. Biol. 22, 4124-4135. DOI
36	del Monte, F., Hajjar, R. J. and Harding, S. E. (2001) Overwhelming evidence of the beneficial effects of SERCA gene transfer in heart failure. Circ. Res. 88, E66-67. DOI
37	del Monte, F., Harding, S. E., Schmidt, U., Matsui, T., Kang, Z. B., Dec, G. W., Gwathmey, J. K., Rosenzweig, A. and Hajjar, R. J. (1999) Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 100, 2308-2311. DOI ScienceOn
38	Endo, S., Zhou, X., Connor, J., Wang, B. and Shenolikar, S. (1996) Multiple structural elements define the specificity of recombinant human inhibitor-1 as a protein phosphatase-1 inhibitor. Biochemistry 35, 5220-5228. DOI ScienceOn
39	Gupta, R. C., Neumann, J., Watanabe, A. M., Lesch, M. and Sabbah, H. N. (1996) Evidence for presence and hormonal regulation of protein phosphatase inhibitor-1 in ventricular cardiomyocyte. Am. J. Physiol. 270, H1159-1164.
40	Jaski, B. E., Jessup, M. L., Mancini, D. M., Cappola, T. P., Pauly, D. F., Greenberg, B., Borow, K., Dittrich, H., Zsebo, K. M. and Hajjar, R. J. (2009) Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J. Card. Fail. 15, 171-181. DOI ScienceOn
41	Jessup, M., Greenberg, B., Mancini, D., Cappola, T., Pauly, D. F., Jaski, B., Yaroshinsky, A., Zsebo, K. M., Dittrich, H. and Hajjar, R. J. (2011) Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124, 304-313. DOI ScienceOn
42	Ji, Y., Lalli, M. J., Babu, G. J., Xu, Y., Kirkpatrick, D. L., Liu, L. H., Chiamvimonvat, N., Walsh, R. A., Shull, G. E. and Periasamy, M. (2000) Disruption of a single copy of the SERCA2 gene results in altered Ca2+ homeostasis and cardiomyocyte function. J. Biol. Chem. 275, 38073-38080. DOI ScienceOn
43	Braz, J. C., Gregory, K., Pathak, A., Zhao, W., Sahin, B., Klevitsky, R., Kimball, T. F., Lorenz, J. N., Nairn, A. C., Liggett, S. B., Bodi, I., Wang, S., Schwartz, A., Lakatta, E. G., DePaoli-Roach, A. A., Robbins, J., Hewett, T. E., Bibb, J. A., Westfall, M. V., Kranias, E. G. and Molkentin, J. D. (2004) PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat. Med. 10, 248-254. DOI ScienceOn
44	Byrne, M. J., Power, J. M., Preovolos, A., Mariani, J. A., Hajjar, R. J. and Kaye, D. M. (2008) Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther. 15, 1550-1557. DOI ScienceOn
45	Houser, S. R., Piacentino, V. 3rd and Weisser, J. (2000) Abnormalities of calcium cycling in the hypertrophied and failing heart. J. Mol. Cell Cardiol. 32, 1595-1607. DOI ScienceOn
46	Hasenfuss, G., Reinecke, H., Studer, R., Meyer, M., Pieske, B., Holtz, J., Holubarsch, C., Posival, H., Just, H. and Drexler, H. (1994) Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ. Res. 75, 434-442. DOI ScienceOn

Reference

348	J. Lauriol. (2014) Science Signaling RhoA signaling in cardiomyocytes protects against stress-induced heart failure but facilitates cardiac fibrosis / 7 (348) , ra100
4	Sha Li. (2017) Journal of Cardiovascular Pharmacology Liguzinediol Enhances the Inotropic Effect of Rat Hearts via Inhibition of Protein Phosphatase (PP1 and PP2A) Activities / 69 (4) , 236
4	Ahyoung Lee. (2016) Heart, Lung and Circulation Post-translational Modifications in Heart Failure: Small Changes, Big Impact / 25 (4) , 319
37	Neha Abrol. (2014) Journal of Biological Chemistry Phospholamban C-terminal Residues Are Critical Determinants of the Structure and Function of the Calcium ATPase Regulatory Complex / 289 (37) , 25855
	Wenjing Hu. (2017) Scientific Reports Luteolin improves cardiac dysfunction in heart failure rats by regulating sarcoplasmic reticulum Ca2+-ATPase 2a / 7 , 41017
7	Ling-hui Lu. (2017) Chinese Journal of Integrative Medicine Cardioprotective effects of Qishen Granule (芪参颗粒) on sarcoplasmic reticulum Ca2+ handling in heart failure rats / 23 (7) , 510
4	Israr Ahmad. (2017) Photochemistry and Photobiology Ultraviolet Radiation-Induced Downregulation of SERCA2 Mediates Activation of NLRP3 Inflammasome in Basal Cell Carcinoma / 93 (4) , 1025
12	Xiaohong T. Gan. (2015) The American Journal of Pathology Myocardial Hypertrophic Remodeling and Impaired Left Ventricular Function in Mice with a Cardiac-Specific Deletion of Janus Kinase 2 / 185 (12) , 3202
10	Andrew N. Stammers. (2015) Canadian Journal of Physiology and Pharmacology The regulation of sarco(endo)plasmic reticulum calcium-ATPases (SERCA)1 / 93 (10) , 843
8	Qibin Jiao. (2014) Clinical and Experimental Pharmacology and Physiology αB-Crystallin R120G variant causes cardiac arrhythmias and alterations in the expression of Ca2+-handling proteins and endoplasmic reticulum stress in mice / 41 (8) , 589
1	S. A. Afanasiev. (2017) Human Physiology Differences in the force–interval relationship of isolated human myocardium with chronic coronary artery disease with and without type 2 diabetes mellitus and the role of sarcoplasmic reticulum Ca2+-ATPase / 43 (1) , 54
5	George H. Kunkel. (2016) Heart Failure Reviews Mitochondrial pathways to cardiac recovery: TFAM / 21 (5) , 499
	Estefanía Tarazón. (2017) The Journal of Heart and Lung Transplantation SERCA2a: A potential non-invasive biomarker of cardiac allograft rejection /
2	(2018) Canadian Journal of Physiology and Pharmacology Mechanisms of TFAM-mediated cardiomyocyte protection / 96 (2) , 173
1029-2470	(2018) Free Radical Research Mitochondria regulate cardiac contraction through ATP-dependent and independent mechanisms / (1029-2470) , 1
2	(2018) International Journal of Molecular Sciences HDAC Inhibition Improves the Sarcoendoplasmic Reticulum Ca2+-ATPase Activity in Cardiac Myocytes / 19 (2) , 419
10	(2018) Circulation Research Overload and Contractile Dysfunction in a Mouse Model of Myocardial Infarction / 122 (10) , 1354
4	(2018) Diabetes and Vascular Disease Research Altered sarco(endo)plasmic reticulum calcium adenosine triphosphatase 2a content: Targets for heart failure therapy / 15 (4) , 322